Sugi Predict

Sugi Predict / Compounds / SCHEMBL111192

SCHEMBL111192

SCHEMBL111192

OCc1ccc(OBOc2ccc(CO)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 1/20 0.52
▸ PPARA Q07869 3/20 0.42
▸ PPARG P37231 2/20 0.42
▸ TSHR P16473 1/20 0.42
▸ PRSS1 P07477 1/20 0.38
▸ PRSS2 P07478 1/20 0.38
▸ PRSS3 P35030 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ VHL P40337 1/20 0.37
▸ ELOC Q15369 1/20 0.37
▸ ELOB Q15370 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA4 P22748 1/20 0.37
▸ CA6 P23280 1/20 0.37
▸ CA5A P35218 1/20 0.37
▸ CA7 P43166 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264174 0.83 CA2 (0.52) LTA4HPPARATSHRHRH3CA12
SCHEMBL819826 0.83 LTA4H (0.50) LTA4HPPARAPPARGTSHRPRSS1
SCHEMBL3321418 0.78 LTA4H (0.53) LTA4HPPARAHRH3CA2MEN1
SCHEMBL5342317 0.76 LTA4H (0.81) LTA4HPPARAPPARGTSHRPRSS1
SCHEMBL1191309 0.75 HRH3 (0.38) HRH3
SCHEMBL1427275 0.75 TRPA1 (0.42) TSHR
SCHEMBL489178 0.75 SMN1; SMN2 (0.44) —
SCHEMBL553009 0.75 ST14 (0.54) HRH3
SCHEMBL41775 0.74 TSHR (0.67) LTA4HPPARAPPARGTSHRPRSS1
SCHEMBL15417600 0.74 LTA4H (0.62) LTA4HPPARAPPARGTSHRPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545860-B2 Mannanase variants BASF SE (DE) 2026-02-10 — — US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-06-26 — — US disclosed
WO-2025129135-A2 COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-06-19 — — WO disclosed
CN-119732906-A Nanometer micelle with inflammatory microenvironment response and preparation method and application thereof 吉林大学 2025-04-01 — — CN disclosed
CN-119552120-A Pyrazole and imidazole compounds for inhibiting IL-17 and rory 里亚塔医药公司 2025-03-04 — — CN disclosed
CN-112654610-B Pyrazole and imidazole compounds for inhibiting IL-17 and rory 里亚塔医药公司 2024-12-24 — — CN disclosed
WO-2024148272-A1 AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS RIBOSCIENCE LLC (US) 2024-07-11 — — WO disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 — — CN disclosed
CN-114105976-B Selective ROCK2 kinase inhibitors 杭州邦顺制药有限公司 2024-04-26 — — CN disclosed
WO-2002096867-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG BIOMEDICAL INSTITUTE (US) 2002-12-05 — — WO disclosed
WO-2002094823-A1 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2002-11-28 — — WO disclosed
US-20020010183-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-01-24 — — US disclosed
WO-2001087882-A2 SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-11-22 — — WO disclosed
EP-0724566-B1 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 1998-10-07 — — EP disclosed
US-5663180-A ANTIARTHRITIC, ANTIINFLAMMATORY AGENTS G.D. SEARLE & CO. (US) 1997-09-02 — — US disclosed
EP-0724566-A1 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-07 — — EP disclosed
US-5420287-A 1,2 diarylcyclopentenyl compounds for the treatment of inflammation G. D. SEARLE & CO. (US) 1995-05-30 — — US disclosed
WO-1995011883-A1 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1995-05-04 — — WO disclosed
US-5344991-A Sulfonyl or sulfamyl derivatives for treatment of arthritis and pain G.D. SEARLE & CO. (US) 1994-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 LTA4H 818/4885PPARA 2130/4885PPARG 3050/4885
US-12545860-B2 Mannanase variants MAN2A1, MANBA, IDUA LTA4H 3105/4885PPARA 4882/4885PPARG 4883/4885
US-20020010183-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors PDE5A, PDE3A, PDE3B LTA4H 1702/4885PPARA 2072/4885PPARG 1361/4885
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL LTA4H 2832/4885PPARA 4133/4885PPARG 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.